Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.

Presenters:
Jesus G. Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research 
Partner
Tennessee Oncology
Nashville, Tennessee

Ajai Chari, MD
Professor of Clinical Medicine
Director of Multiple Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) Medical Center
San Francisco, California

Content based on an online CME program supported by an educational grant from GSK.

Link to full program:
https://bit.ly/3TZSmuf

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Decera Clinical Education. Innehållet i podden är skapat av Decera Clinical Education och inte av, eller tillsammans med, Poddtoppen.